Also known as CJC-1295 DAC
Long-acting GHRH analog with a Drug Affinity Complex for albumin binding.
Adds a maleimidopropionic acid (DAC) moiety to modified GRF(1-29), enabling covalent binding to serum albumin and extending half-life to roughly 6–8 days.
CJC-1295 with DAC adds a Drug Affinity Complex — a maleimidopropionic acid group — to Modified GRF(1-29), allowing the peptide to bind covalently to serum albumin. This extends its half-life to roughly 6–8 days, replacing the brief pulse of the no-DAC form with prolonged elevation.
The trade-off studied in the literature is physiologic: sustained GHRH-receptor exposure raises baseline GH and IGF-1 but blunts the natural pulsatility of the GH axis. It is a research compound and is not FDA-approved.
GHRH receptor agonism with albumin-mediated extended exposure.
Behind every vial of CJC-1295 (with DAC) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how CJC-1295 (with DAC), specifically, is brought into being.
CJC-1295 (with DAC) begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
CJC-1295 (with DAC) is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — CJC-1295 (with DAC) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of CJC-1295 (with DAC) proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of CJC-1295 (with DAC) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing CJC-1295 (with DAC) to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning CJC-1295, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A long-acting GHRH analog whose Drug Affinity Complex binds albumin, extending its half-life to roughly a week for sustained GH and IGF-1 elevation.
The no-DAC form produces a brief GH pulse; the DAC form gives prolonged elevation by binding albumin, at the cost of natural pulsatility.
A chemical group that lets the peptide covalently attach to serum albumin, dramatically slowing its clearance.
No — it is a research compound. This page is a research and educational reference.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.